Sugi Predict

Sugi Predict / Compounds / SCHEMBL23723405

SCHEMBL23723405

SCHEMBL23723405

[2H]C([2H])([2H])N(CCc1c[nH]c2cccc(OCc3ccccc3)c12)C([2H])([2H])[2H]

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 8/20 0.84
▸ HTR6 P50406 2/20 0.57
▸ HTR2C P28335 4/20 0.51
▸ HTR2B P41595 4/20 0.51
▸ HTR1A P08908 3/20 0.51
▸ HTR1D P28221 4/20 0.50
▸ TRPM8 Q7Z2W7 2/20 0.50
▸ DRD1 P21728 1/20 0.47
▸ HTR1B P28222 1/20 0.47
▸ HTR1E P28566 1/20 0.47
▸ ADORA2A P29274 1/20 0.47
▸ ADORA2B P29275 1/20 0.47
▸ HTR7 P34969 1/20 0.47
▸ DRD3 P35462 1/20 0.47
▸ HTR5A P47898 1/20 0.47
▸ SLC6A4 P31645 1/20 0.43
▸ LTA4H P09960 1/20 0.43
▸ PLA2G2A P14555 1/20 0.43
▸ MITF O75030 1/20 0.41
▸ LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12558834 0.92 HTR2A (1.00) HTR2AHTR6HTR2CHTR2BHTR1A
SCHEMBL29511892 0.92 HTR2A (1.00) HTR2AHTR6HTR2CHTR2BHTR1A
SCHEMBL29361521 0.85 HTR2A (1.00) HTR2AHTR6HTR2CHTR2BHTR1A
SCHEMBL5770609 0.85 HTR2A (0.78) HTR2AHTR6HTR2CHTR2BHTR1A
SCHEMBL4206922 0.84 HTR2A (0.77) HTR2AHTR6HTR2CHTR2BHTR1A
SCHEMBL23805249 0.84 HTR2A (0.80) HTR2AHTR6HTR2CHTR2BHTR1A
SCHEMBL23805214 0.83 HTR2A (0.79) HTR2AHTR6HTR2CHTR2BHTR1A
SCHEMBL23805277 0.83 HTR2A (0.79) HTR2AHTR6HTR2CHTR2BHTR1A
SCHEMBL26307651 0.83 HTR2A (0.83) HTR2AHTR6HTR2CHTR2BHTR1A
SCHEMBL29992570 0.83 HTR6 (0.82) HTR2AHTR6HTR2CHTR2BHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388611-A1 PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS MINDSET PHARMA, INC. (CA) 2025-12-25 — — US disclosed
US-20240342126-A1 HALLUCINOGEN-FATTY ACID COMBINATION MINDSET PHARMA INC. (CA) 2024-10-17 — — US disclosed
US-12054505-B2 Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders MINDSET PHARMA INC. (CA) 2024-08-06 — — US disclosed
US-20230167141-A1 PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS MINDSET PHARMA INC. (CA) 2023-06-01 — — US disclosed
US-20230118872-A1 PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS MINDSET PHARMA INC. (CA) 2023-04-20 — — US disclosed
CN-115974757-A Silodosin derivatives as serotonergic hallucinogens for the treatment of CNS disorders 明德赛特制药公司 2023-04-18 — — CN disclosed
US-11591353-B2 Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders MINDSET PHARMA INC. (CA) 2023-02-28 — — US disclosed
EP-4100391-A1 PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS Mindset Pharma Inc. (CA) 2022-12-14 — — EP disclosed
CN-115397810-A Silodosin derivatives as serotonergic hallucinogens for the treatment of CNS disorders 明德赛特制药公司 2022-11-25 — — CN disclosed
US-20220324889-A1 PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS MINDSET PHARMA INC. (CA) 2022-10-13 — — US disclosed
US-20220024956-A1 PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS MINDSET PHARMA INC. (CA) 2022-01-27 — — US disclosed
WO-2021155470-A1 PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS MINDSET PHARMA INC. (CA) 2021-08-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324889-A1 PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS HTR1A, HTR6, HTR1B HTR2A 4/4885HTR6 2/4885HTR2C 7/4885
US-20240342126-A1 HALLUCINOGEN-FATTY ACID COMBINATION FAAH, HTR5A, FAAH2 HTR2A 8/4885HTR6 7/4885HTR2C 5/4885
US-20230118872-A1 PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS HTR1A, HTR6, HTR1B HTR2A 4/4885HTR6 2/4885HTR2C 7/4885
US-20220024956-A1 PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS HTR1A, HTR6, HTR1B HTR2A 4/4885HTR6 2/4885HTR2C 7/4885
US-12054505-B2 Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders HTR1A, HTR6, HTR1B HTR2A 4/4885HTR6 2/4885HTR2C 7/4885
US-11591353-B2 Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders HTR1A, HTR6, HTR1B HTR2A 4/4885HTR6 2/4885HTR2C 7/4885
US-20250388611-A1 PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS HTR6, CNR1, HTR1D HTR2A 16/4885HTR6 1/4885HTR2C 5/4885
US-20230167141-A1 PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS HTR1A, HTR6, HTR1B HTR2A 4/4885HTR6 2/4885HTR2C 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.